Report Description

Concerns over efficacy, cost, and drug safety have stimulated a need for personalized medicine; and for improving the predictability of clinical and pre-clinical research to reduce development cost and time. The use of biomarkers is no longer restricted only to the identification of non-responder or responder population for therapeutic purposes. Biomarkers have now gained significant importance in the drug development process, and the market is thus perceived as an emerging but lucrative segment that is opening up new opportunities. It is therefore crucial to gain an understanding of the market dynamics, market size, and competitive landscape. However, most of the available reports do not provide a holistic analysis of biomarker market and neither do they focus on the micro-markets. This report’s exhaustive market segmentation captures relevant data pertaining to biomarker tools, services, and application markets, and thereby provides a complete picture of the biomarkers market.

Scope of the report

The report categorizes the global biomarker market as follows:

• Tools Market (pre-genomic biomarkers and technologies, post-genomic biomarkers and technologies, imaging biomarkers, and others)
• Services Market (pre- and post-clinical biomarker services, sample preparation, mirna analysis, and others)
• Application Market (diagnosis, drug development and discovery)

What makes our reports unique?

1. We provide the longest market segmentation chain in the industry with our three-level market breakdown and our analysis of minimum 40 collectively exhaustive and mutually exclusive micro markets.
2. We provide 10% customization to ensure that our clients find the specific market intelligence they need.
3. Each report is about 150 pages, featuring 30+ market data tables, 30+ company profiles, and an analysis of 200 patents.
4. No single report by any other publisher provides market data for all market segments (i.e. products, services, applications, ingredients, and technology) covering the four geographies of North America, Europe, Asia Pacific, and ROW.
5. 15 pages of high level analysis identifying opportunities, best practices, entry strategies, benchmarking strategies, market positioning, product positioning, and competitive positioning.

Key questions answered

1. Which are the high-growth segments and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
2. What are market estimates and forecasts; which markets are doing well and which are not?
3. Where are the gaps and opportunities; what factors are driving market growth?
4. Which are the key playing fields and winning-edge imperatives?
5. What is the competitive landscape; who are the main players in each segment; what are their strategic directives, operational strengths, key selling products, and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies.

Table of Content

1. market overview

1.1. Defining biomarker

1.2. Defining the biomarker market

1.3. Biomarker and its applications- Holistic view with respect to diagnosis and drug discovery

1.4. Cardiovascular and cancer diagnosis applications have high priority in the existing and future market scenario

1.5. Biomarker Pre and Post clinical services impacting the biomarker services market

1.6. biomarker patent analysis

2. summary

3. biomarker market dynamics

3.1. Drivers

3.1.1. high demand for biomarkers in drug discovery

3.1.2. BIOMARKERs help in the Early detection of drug failures

3.1.3. Biomarkers as cancer diagnostic tools

3.1.4. Cro RECOGNIZE VALUE OF biomarkerS IN drug development

3.1.5. Development in the life science fields such as proteomics and genomics enhances the biomarker applications

3.1.6. Support from FDA for biomarker development

3.2. Restraints

3.2.1. regulatory environment restrains the market growth

3.2.2. High initial investment hinders biomarker applicability

3.2.3. biomarker tests perceived to be unreliable

3.2.4. disapproval of diagnotic tools for biomarkers hinders the market growth

3.2.5. Biomarker validation approaches still not clearly addressed

3.2.6. Lack of web based solutions for biomarker discovery

3.3. Opportunities

3.3.1. Translational medicine focus on biomarker

3.3.2. accurate and precise measures of diseases

3.3.3. Commercial applications in proteomics

4. global biomarker tools market

4.1. Drivers:

4.1.1. effective software solutions boost biomarker tools

4.1.2. Discovery of cancer biomarkers

4.2. Pregenomic Biomarkers and Technologies

4.2.1. Drivers

4.2.1.1. Discovery of new biomarkers stimulates development of technologies

4.2.1.2. Quick diagnosis offered by molecular diagnostics boosts the growth

4.2.2. Molecular Diagnostics

4.2.3. Drivers:

4.2.3.1. Need for easy to handle and automated techniques drives the market

4.2.3.2. Technological push supports the market growth

4.2.4. Immunodiagnostics

4.2.5. Drivers:

4.2.5.1. Emerging applications of immunoassays supports immunodiagnostics market

4.2.5.2. Need for timely diagnosis and early detection of diseases has spurred the growth

4.2.6. Restraints

4.2.6.1. Price erosion hinders the market growth

4.2.6.2. Lack of standardization hampers market development

4.2.7. Enzyme and Metabolite Assays

4.3. Postgenomic Biomarkers and Technologies

4.4. Drivers

4.4.1. High demand for medical requirements boosts technological growth

4.4.2. greater stress on individual risk assessment

4.5. Restraints

4.5.1. High cost of genomics platform

4.5.2. FDA approval poses a big challenge for market participants

4.6. Opportunities

4.6.1. Emerging field of nutrition research to support the market growth

4.6.2. Proteomics

4.6.3. Drivers

4.6.3.1. Need to enhance the efficiency and speed of drug discovery process

4.6.3.2. Potential of proteomics in personalized therapy development

4.6.4. Restraints

4.6.4.1. Expensive proteomics analysis tools leads to low adoption rates

4.6.4.2. Technological need for speeding up validation process

4.6.5. Mass Spectrometry in Biomarker Discovery and Validation

4.6.6. Drivers

4.6.6.1. Easy quantification of the protein structures created the need for mass spectrometry

4.6.6.2. Rising popularity of integrated MS tools boosts the growth

4.6.7. Metabolomics

4.6.8. Drivers

4.6.8.1. Emergence of “omics” sciences in the field of drug development spurs the market size.

4.6.8.2. Rapid growth of metabolomics data analysis software and solution

4.6.9. 2D Gel Electrophoresis

4.6.10. Differential In-gel Electrophoresis

4.6.11. Transcriptomics

4.6.11.1. Positional DNA Microarrays

4.6.11.2. Encoded Particle Arrays

4.6.12. Analysis of Metabolites in Biological Specimens

4.6.12.1. Disease-Related Biomarkers

4.6.12.2. Metabolite Profiling for Biomarker Discovery

4.6.13. Imaging Biomarkers

4.6.14. Drivers

4.6.14.1. Rising applications of imaging biomarkers in the drug development

4.6.14.2. Success of imaging biomarkers in several diseases

4.6.14.3. Molecular Imaging

4.6.14.4. Magnetic Resonance Imaging

4.6.14.5. Positron Emission Tomography

4.6.14.6. FDG-PET Patient Phase I Studies

4.6.14.7. Imaging Biomarkers as Study Endpoints

4.6.15. Others

4.6.15.1. Bioinformatics

4.6.15.2. Reagents

5. global biomarker services market

5.1. Drivers

5.1.1. emergence of contract research organizations as service providers

5.1.2. High ROI from investment in biomarker discovery by the PHARMACEUTICAL INDUSTRY

5.2. Biomarker Pre and Post Clinical Services

5.3. Drivers

5.3.1. Biomarkers boost the efficiency in the drug discovery process.

5.3.2. High duration and cost of the clinical trials drives the services

5.3.3. Biomarker Testing

5.3.4. Assay Development

5.4. Antibody Development

5.4.1. Validation and Reporting

5.5. Sample Preparation

5.5.1. Blood/biofluids

5.5.2. Cell lines - eukaryotic and prokaryotic

5.5.3. Frozen/RNAlater/RNAretain tissues

5.6. Other services

5.6.1. Bioinformatics Services

5.6.2. Data Analysis

5.6.3. mRNA Analysis

5.7. miRNA Analysis

5.7.1. miRNA Microarray Service

5.7.2. miRNA Expression Profiling

6. global biomarker applications market

6.1. Drivers:

6.1.1. Demand for early predictive technologies into pre-clinical and early clinical development phase

6.1.2. Developments in high-throughput technologies, systems biology and bioinformatics

6.1.3. Development of safer drugs with increased therapeutic efficacy in a cost-effective manner

6.1.4. Less expense of genetic biomarkers incorporated for genotyping boosting the demand for the same.

6.2. Restraints:

6.2.1. Biomarker without clinical validation generates erroneous end points

6.2.2. Large varieties of biomarkers delay evaluation, clinically

6.2.3. Uncertainties in Pharmacogenomics Testing Hinders Market Adoption

6.2.4. Ethical Issues regarding Patient’s Confidentiality and Rights Pose another Area of concern.

6.3. Diagnosis

6.3.1. Cancer Diagnosis

6.4. Market Drivers:

6.4.1. Adoption of biomarker for cancer diagnosis

6.4.2. Current development and research driving the biomarker market for cancer diagnosis.

6.4.2.1. Ovarian Cancer Diagnostics

6.4.2.2. HER2 Breast cancer Diagnostics

6.4.2.3. Bladder Cancer

6.4.2.4. Cervical Cancer Diagnostics

6.4.2.5. Prostate Cancer

6.4.3. Cardiovascular and Metabolic Diseases:

6.5. Market Drivers:

6.5.1. Cardiovascular Biomarkers potential to accurately detect heart failure.

6.5.2. Biomarkers facilitate enhanced diagnosing and managing metabolic disease

6.6. Restraints

6.6.1. Specific technical requirements are unmet

6.6.2. Autoimmune disease and inflammatory diseases

6.7. Drivers

6.7.1. Need for effective treatment and diagnosis

6.8. Restraints

6.8.1. Lack of understanding of the disease cause among researchers and scientists.

6.8.2. Neurological Diseases:

6.9. Drivers

6.9.1. Patients demand for rapid diagnosis and treatment

6.9.2. Precaution and effective clinical diagnosis for autoimmune diseases

6.10. Restraints

6.10.1. Limitations in the reimbursement systems

6.10.2. The costs for diagnostics are starting to be offset against the savings in other areas

6.10.2.1. Alzheimer’s disease

6.10.2.1.1. Image based biomarkers

6.10.2.1.2. Genetic Markers

6.10.2.1.3. Biomarkers in blood:

6.10.2.1.4. Biomarkers in cerebrospinal fluid

6.10.2.2. Schizophrenia:

6.10.2.3. Parkinson’s disease:

6.10.3. Tuberculosis:

6.11. Market DRiver

6.11.1. Biomarkers ability to accelerate and streamline drug development for tuberculosis.

6.11.2. Rise in the drug resistant tuberculosis

6.11.2.1. Stroke Diagnosis

6.12. Driver

6.12.1. Rising incidence of stroke globally has boosted the need for biomarkers

6.12.2. Transition in dietary intake globally

6.13. Drug Development & Discovery

6.13.1. Drug Targets

6.13.1.1. Target Validation

6.13.1.1.1. Target Discovery

6.13.1.2. Target Discovery Using Functional Genomics

6.13.2. ADME-TOX profiling

6.13.3. Drug development and process quality assurance

7. ographical analysis of biomarker market

7.1. north america:

7.2. Europe:

7.3. Asia:

7.4. row:

8. competitive landscape

9. company profiles

9.1. Affymetrix

9.2. Agilent Technologies

9.3. Amgen

9.4. Ariadne

9.5. Banyan Biomarkers Inc.

9.6. BG Medicine

9.7. Biophysical Corp

9.8. BioSystems International (BSI)

9.9. Calibrant

9.10. Caprion Proteomics

9.11. Correlogic Systems Inc

9.12. Cyclacel

9.13. deCODE

9.14. Epigenomics

9.15. Exagen Diagnostics Inc.

9.16. GE Healthcare

9.17. Genedata

9.18. GeneGo

9.19. GeneNews

9.20. Gyros AB

9.21. Human Metabolome Technologies (HMT)

9.22. Illumina Inc

9.23. Imgenex

9.24. InforSense

9.25. Ingenuity Systems

9.26. Insilicos

9.27. Integromics

9.28. MDS Inc

9.29. Metabolon Inc

9.30. Metanomics Health GmBH

9.31. MicroDiscovery

9.32. Molecular Connections

9.33. Nanogen

9.34. NextGen Group PLC

9.35. Nonlinear USA Inc

9.36. Nuvera Biosciences

9.37. Ocimum Biosolutions

9.38. Pam Gene BV

9.39. Partek

9.40. Pronota

9.41. Perlegen

9.42. Phenomenome Discoveries Inc

9.43. Siemens Healthcare

9.44. Singulex

9.45. Softgenetics llc

9.46. Tyrian

9.47. Zeptosens

9.48. Patents for united states

9.49. Patents for europe

9.50. Patents for japan

LIST OF TABLES

SUMMARY TABLE Global biomarker market BY tools and services 2009 - 2014 ($ thousands)

Table 1 Global Bio marker Tools market by Product 2007-2014 ($ thousands)

Table 2 Global Bio marker Tools market by Geography 2007-2014 ($ thousands)

Table 3 Global Pregenomic Biomarkers and Technologies market by Product 2007-2014 ($ thousands)

Table 4 Global Pregenomic Biomarkers and Technologies market by Geography 2007-2014 ($ thousands)

Table 5 Global Molecular Diagnostics market by Product 2007-2014 ($ thousands)

Table 6 Global Molecular Diagnostics market byGeography 2007-2014 ($ thousands)

Table 7 Global Immunodiagnostics market by Geography 2007-2014 ($ thousands)

Table 8 Global Enzyme and Metabolite Assays market byGeography 2007-2014 ($ thousands)

Table 9 Global Post genomic Bio markers and Technologies market by Product 2007-2014 ($ thousands)

Table 10 Global Post genomic Bio markers and Technologies market by Geography 2007-2014 ($ thousands)

Table 11 Global Proteomics market by Product 2007-2014 ($ thousands)

Table 12 Global Proteomics market by Geography 2007-2014 ($ thousands)

Table 13 Global Mass Spectrometry in Bio marker Discovery and Validation market by Geography 2007-2014 ($ thousands)

Table 14 Global Metabolomics market by Geography 2007-2014 ($ thousands)

Table 15 Global 2D Gel Electrophoresis market by Geography 2007-2014 ($ thousands)

Table 16 Global Differential In-gel Electrophoresis market by Geography 2007-2014 ($ thousands)

Table 17 Global Transcriptomics market by Product 2007-2014 ($ thousands)

Table 18 Global Transcriptomics market by Geography 2007-2014 ($ thousands)

Table 19 Global Positional DNA Microarrays market by Geography 2007-2014 ($ thousands)

Table 20 Global Encoded Particle Arrays market by Geography 2007-2014 ($ thousands)

Table 21 Global Analysis of Metabolites in Biological Specimens market by Product 2007-2014 ($ thousands)

Table 22 Global Analysis of Metabolites in Biological Specimens market by Geography 2007-2014 ($ thousands)

Table 23 Global Disease-Related Biomarkers market byGeography 2007-2014 ($ thousands)

Table 24 Global Metabolite Profiling for Bio marker Discovery market by Geography 2007-2014 ($ thousands)

Table 25 Global Imaging Biomarkers market by Product 2007-2014 ($ thousands)

Table 26 Global Imaging Biomarkers market by Geography 2007-2014 ($ thousands)

Table 27 Global Molecular Imaging market by Geography 2007-2014 ($ thousands)

Table 28 Global Magnetic Resonance Imaging market by Geography 2007-2014 ($ thousands)

Table 29 Global Positron Emission Tomography market by Geography 2007-2014 ($ thousands)

Table 30 Global FDG-PET Patient Phase I Studies market by Geography 2007-2014 ($ thousands)

Table 31 Global Imaging Bio markers as Study Endpoints market by Geography 2007-2014 ($ thousands)

Table 32 Global Others market by Product 2007-2014 ($ thousands)

Table 33 Global Others market by Geography 2007-2014 ($ thousands)

Table 34 Global Bioinformatics market by Geography 20072014 ($ thousands)

Table 35 Global Reagents market by Geography 2007-2014 ($ thousands)

Table 36 Global Biomarker Services market by Product 2007-2014 ($ thousands)

Table 37 Global Bio marker Services market by Geography 2007-2014 ($ thousands)

Table 38 Global Biomarker Pre and Post Clinical Services market by product 2007-2014 ($ thousands)

Table 39 Global Biomarker Pre and Post Clinical Services market by Geography 2007-2014 ($ thousands)

Table 40 Global Biomarker Testing market by Geography 2007-2014 ($ thousands)

Table 41 Global Assay Development market by Geography 2007-2014 ($ thousands)

Table 42 Global Antibody Development market by Geography 2007-2014 ($ thousands)

Table 43 Global Validation and Reporting market by Geography 2007-2014 ($ thousands)

Table 44 Global Sample Preparation market by Product 2007-2014 ($ thousands)

Table 45 Global Sample Preparation market by Geography 2007-2014 ($ thousands)

Table 46 Global Blood/bio fluids market by Geography 2007 - 2014 ($ thousands)

Table 47 Global Cell lines - eukaryotic and prokaryotic market by Geography 2007 - 2014 ($ thousands)

Table 48 Global Frozen/RNAlater/RNAretain tissues marketby Geography 2007-2014 ($ thousands)

Table 49 Global other services market by product 2007-2014 ($ thousands)

Table 50 Global other services market by geography 2007-2014 ($ thousands)

Table 51 Global bioinformatics services market BY GEOGRAPHY 2007-2014 ($ thousands)

Table 52 Global data analysis market by geography 2007-2014 ($ thousands)

Table 53 Global mrna analysis market by geography 2007-2014($ thousands)

Table 54 Global mirna analysis market by product 2007-2014 ($ thousands)

Table 55 Global mirna analysis market by geography 2007-2014 ($ thousands)

Table 56 Global mirna microarray service market by geography 2007-2014 ($ thousands)

Table 57 Global miRNA expresion profiling market by geography 2007-2014 ($ thousands)

Table 58 Global biomarker applications market 2007-2014 ($ thousands)

Table 59 Global diagnosis market by product 2007-2014 ($ thousands)

Table 60 Global cancer diagnosis market by product 2007-2014 ($ thousands)

Table 61 Global neurological disease market by product 2007-2014 ($ thousands)

Table 62 Global alzheimer’s disease market by product 2007-2014 ($ thousands)

Table 63 Global drug development and discovery market by product 2007-2014 ($ thousands)

Table 64 Global drug target market by product 2007-2014 ($ thousands)

Table 65 Global target validation market by product 2007-2014 ($ thousands)

TABLE 66 NORTH AMERICAn BIOmarker MARKET 2007-2014 ($ thousands)

TABLE 67 european BIOmarker MARKET 2007-2014 ($ thousands)

TABLE 68 asian BIOmarker MARKET 2007-2014 ($ thousands)

TABLE 69 row BIOmarker MARKET 2007-2014 ($ thousands)

table 70 NEW PRODUCT, TECHNOLOGY, SERVICE LAUNCH (2008-2009)

table 71 list of agreements and collaborations (2008-2009)

LIST OF FIGURES

Figure 1 biomarker discovery

figure 2 evolution of biomarkers and future shift Defining the biomarker market

Figure 3 Biomarker market segmentation

figure 4 Business architecture

figure 5 biomarker opportunity

figure 6 biomarker challenges

figure 7 biomarker applications market prospective

Figure 8 Biomarker applications market dynamics

Figure 9 Biomarker services markeT dynamics

figure 10 patent analysis by technology 2006 to 2008

figure 11 Patent analysis by competitors (2004-2008)

figure 12 patent analysis by geography

Figure 13 Biomarker clinical trial effectiveness

Figure 14 Biomarker applications in molecular diagnostics

Figure 15 imaging biomarkers APPLICATIONS in drug development

Figure 16 Common bioinformatics microarrays for biomarker discovery

Figure 17 Biomarker areas in drug development process

Figure 18 Global biomarker market by geography

Figure 19 Global biomarker tools market by geography

Figure 20 Global biomarker service market by geography

figure 21 geography wise biomarker market- global perspective

figure 22 Major segments focused by global biomarker players

Figure 23 Competitive landscape for strategy formation (2008-2009)

The Global Biomarker Market report analyzes the biomarker tools and services market over the period 2009-2014. The report studies the major market drivers, restraints, and opportunities for the global biomarker market; and also evaluates the major trends in the macro- and micro-markets with respect to different geographic regions.

Concerns over efficacy, cost and drug safety has ignited the personalized medicine need. There is a vast need of improving the predictability of clinical and pre-clinical research to reduce the development costs and time. Picking the right patient and supervising his progress has become a very common feature for the personalized therapies. The use of biomarker is not only restricted for the identification of non-responder or responder population for the therapeutics purpose but it also has a significant importance in the drug development process. The biomarker market in its growing stage is eyed as a lucrative segment that is opening up new opportunities. Hence understanding the market dynamics, market size and competitive landscape is crucial. However most of the reports that are available do not provide a holistic aspect of biomarker market and do not focus on the micro markets. The market segmentation of this report is exhaustive and captures relevant data pertaining to biomarker tools, services and application markets and thereby providing a complete picture of the biomarkers market.

The global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7 % from 2009 to 2014, driven by the high demand for the biomarkers in the field of drug discovery. The markets for biomarker tools and services are expected to grow at a CAGR of 18.5% and 22.2% respectively. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market. The illustration shows the applications of biomarker in various fields such as cancer. Biomarkers are being intensively applied in the drug discovery and diagnostic applications with the rising demand for technologies for early clinical development phase.

Biomarker Applications

The high growth of biomarker market is boosted by the demand from the baby boomer generation in the U.S., and from Asia’s emerging IT industry. Biomarker applications are increasing in cancer diagnosis as novel tools are being developed to increase the discovery speed of cancer biomarkers. The use of proteomics in biomarker testing and identification has in turn boosted the services for the biomarkers. Market players are now focusing on new product and service development to enhance their commercial portfolios. Strategic collaborations among companies are also increasing biomarker applications in the field of diagnosis and drug discovery.